JP2004534741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534741A5 JP2004534741A5 JP2002576291A JP2002576291A JP2004534741A5 JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5 JP 2002576291 A JP2002576291 A JP 2002576291A JP 2002576291 A JP2002576291 A JP 2002576291A JP 2004534741 A5 JP2004534741 A5 JP 2004534741A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- fragment
- cancer
- antibody
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR3958A AUPR395801A0 (en) | 2001-03-26 | 2001-03-26 | Antibodies against cancer |
| AUPR3958 | 2001-03-27 | ||
| PCT/AU2002/000362 WO2002077033A1 (en) | 2001-03-26 | 2002-03-26 | Antibodies against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Division JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534741A JP2004534741A (ja) | 2004-11-18 |
| JP2004534741A5 true JP2004534741A5 (https=) | 2005-12-22 |
| JP4854912B2 JP4854912B2 (ja) | 2012-01-18 |
Family
ID=3827964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576291A Expired - Fee Related JP4854912B2 (ja) | 2001-03-26 | 2002-03-26 | 癌に対する抗体 |
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188842A Pending JP2009024014A (ja) | 2001-03-26 | 2008-07-22 | 癌に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7318924B2 (https=) |
| EP (1) | EP1383801A4 (https=) |
| JP (2) | JP4854912B2 (https=) |
| KR (1) | KR100909290B1 (https=) |
| CN (2) | CN100457781C (https=) |
| AU (3) | AUPR395801A0 (https=) |
| CA (1) | CA2442318A1 (https=) |
| NZ (1) | NZ528624A (https=) |
| WO (1) | WO2002077033A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| PT1390389E (pt) * | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| AU2003301619A1 (en) * | 2002-10-23 | 2004-05-13 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| WO2004090158A1 (ja) * | 2003-04-03 | 2004-10-21 | Oncorex, Inc. | 医薬品 |
| CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| CA2539116C (en) | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| ES2408704T3 (es) * | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| US7939056B2 (en) * | 2005-11-14 | 2011-05-10 | The Brigham And Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| AU2008260445A1 (en) * | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| KR100973029B1 (ko) * | 2008-10-07 | 2010-08-11 | 박지운 | 알루미늄 합금 가로등 등주 |
| US20100135904A1 (en) * | 2008-11-07 | 2010-06-03 | Research Development Foundation | Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling |
| JP5990752B2 (ja) * | 2011-01-31 | 2016-09-14 | オリンパス株式会社 | 抗体療法の効果増強剤 |
| KR102023496B1 (ko) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| PL3086814T3 (pl) | 2013-12-23 | 2020-12-28 | Bayer Pharma Aktiengesellschaft | Koniugaty środka wiążącego (ADC) z inhibitorami KSP |
| CN107847593B (zh) * | 2015-04-20 | 2021-12-14 | 美侬米克国际有限公司 | 治疗抗体及其用途 |
| RU2751512C2 (ru) | 2015-06-22 | 2021-07-14 | Байер Фарма Акциенгезельшафт | Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы |
| RU2018102358A (ru) | 2015-06-23 | 2019-07-25 | Байер Фарма Акциенгезельшафт | Нацеленные конъюгаты ksp ингибиторов |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| DK0912738T3 (da) | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| CA2358420C (en) | 1999-03-11 | 2010-03-16 | Ardenia Investments Ltd. | New compounds for the treatment of cancer |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| CA2422814A1 (en) | 2000-09-18 | 2002-03-21 | Biogen, Inc. | Cripto mutant and uses thereof |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| PT1390389E (pt) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
-
2001
- 2001-03-26 AU AUPR3958A patent/AUPR395801A0/en not_active Abandoned
-
2002
- 2002-03-26 EP EP02706533A patent/EP1383801A4/en not_active Withdrawn
- 2002-03-26 JP JP2002576291A patent/JP4854912B2/ja not_active Expired - Fee Related
- 2002-03-26 CN CNB028073177A patent/CN100457781C/zh not_active Expired - Fee Related
- 2002-03-26 AU AU2002240719A patent/AU2002240719B2/en not_active Ceased
- 2002-03-26 CA CA002442318A patent/CA2442318A1/en not_active Abandoned
- 2002-03-26 WO PCT/AU2002/000362 patent/WO2002077033A1/en not_active Ceased
- 2002-03-26 US US10/470,013 patent/US7318924B2/en not_active Expired - Fee Related
- 2002-03-26 NZ NZ528624A patent/NZ528624A/xx not_active IP Right Cessation
- 2002-03-26 CN CNA2008101103851A patent/CN101310770A/zh active Pending
-
2003
- 2003-09-26 KR KR1020037012528A patent/KR100909290B1/ko not_active Expired - Fee Related
-
2007
- 2007-04-11 AU AU2007201587A patent/AU2007201587A1/en not_active Abandoned
-
2008
- 2008-07-22 JP JP2008188842A patent/JP2009024014A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534741A5 (https=) | ||
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| JP2008531576A5 (https=) | ||
| Sirotnak et al. | Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase | |
| HRP20151257T1 (hr) | Monoklonska protutijela na klaudin-18 za lijeäśenje karcinoma | |
| JP2008528486A5 (https=) | ||
| NZ528624A (en) | Antibodies against cancer | |
| Park et al. | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma | |
| JP2009505676A5 (https=) | ||
| JP2018534933A5 (https=) | ||
| RU2005132788A (ru) | Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты) | |
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2010535713A5 (https=) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| JP2008503476A5 (https=) | ||
| HRP20150143T1 (hr) | Imunokonjugati koji ciljaju na cd138 i njihova upotreba | |
| Aoki et al. | Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective | |
| JP2007513073A5 (https=) | ||
| JP2015508280A5 (https=) | ||
| JP2011512332A5 (https=) | ||
| HU231064B1 (hu) | Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére | |
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom | |
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения |